

PROVECTUS BIOPHARMACEUTICALS, INC.  
Form 8-K  
September 27, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): September 27, 2016**

**PROVECTUS BIOPHARMACEUTICALS, INC.**  
**(Exact name of registrant as specified in charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of incorporation)**

**001-36457**  
**(Commission**  
  
**File Number)**

**90-0031917**  
**(IRS Employer**  
  
**Identification No.)**

**7327 Oak Ridge Hwy., Knoxville, Tennessee 37931**  
**(Address of Principal Executive Offices)**

**(866) 594-5999**  
**(Registrant's Telephone Number, Including Area Code)**

**(Former Name or Former Address, If Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01. Regulation FD Disclosure.**

On September 27, 2016, Provectus Biopharmaceuticals, Inc. (the Company ), issued a press release (the Press Release ) announcing that the Society for Immunotherapy of Cancer has accepted an abstract for a poster presentation related to the use of PV-10, an investigational ablative immunotherapy under development by the Company for solid tumor cancers, in the treatment of pancreatic cancer. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Pursuant to the rules and regulations of the Securities and Exchange Commission, the information in this Item 7.01 disclosure, including Exhibit 99.1 and information set forth therein, is deemed to have been furnished and shall not be deemed to be filed under the Securities Exchange Act of 1934, as amended.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release, dated September 27, 2016

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 27, 2016

**PROVECTUS BIOPHARMACEUTICALS,  
INC.**

By: /s/ Peter R. Culpepper  
Peter R. Culpepper

Interim Chief Executive Officer and Chief  
Operating Officer

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release, dated September 27, 2016